Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $17.34 down -3.56% from its previous closing price of $17.98. In other words, the price has decreased by -$3.56 from its previous closing price. On the day, 1.74 million shares were traded. DNLI stock price reached its highest trading level at $18.17 during the session, while it also had its lowest trading level at $17.22.
Ratios:
For a deeper understanding of Denali Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.79 and its Current Ratio is at 9.79. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 04 ’25 when CAROLE HO bought 1,882 shares for $19.00 per share.
Schuth Alexander O. sold 2,937 shares of DNLI for $39,884 on Aug 12 ’25. The COFO and Secretary now owns 242,346 shares after completing the transaction at $13.58 per share. On Aug 12 ’25, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 2,937 shares for $13.58 each. As a result, the insider received 39,884 and left with 217,391 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2707786240 and an Enterprise Value of 1739392128.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.04, which has changed by -0.22566754 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $24.34, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 2.04%, while the 200-Day Moving Average is calculated to be 15.49%.
Shares Statistics:
For the past three months, DNLI has traded an average of 1.81M shares per day and 2209680 over the past ten days. A total of 146.63M shares are outstanding, with a floating share count of 138.96M. Insiders hold about 11.01% of the company’s shares, while institutions hold 89.26% stake in the company. Shares short for DNLI as of 1764288000 were 12977218 with a Short Ratio of 7.19, compared to 1761868800 on 13110288. Therefore, it implies a Short% of Shares Outstanding of 12977218 and a Short% of Float of 9.9.
Earnings Estimates
Denali Therapeutics Inc (DNLI) is currently under the scrutiny of 14.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.73 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.86 and -$3.33 for the fiscal current year, implying an average EPS of -$3.01. EPS for the following year is -$2.97, with 13.0 analysts recommending between -$1.94 and -$3.69.
